Press Release -Oslo, Norway ,February 23, 2024 :Photocure ASA (OSE: PHO), theBladder Cancer Company , announces that its partnerAsieris Pharmaceuticals (SSE: 688176) has communicated today that that the international multicenter Phase III clinical study of Cevira[®] (APL-1702), the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions (HSIL), has been selected for late breaking oral presentation at the 2024 SGO Annual Meeting on Women's Cancer of theSociety of Gynecologic Oncology , to be heldMarch 16-18 inSan Diego, CA , USA: · Oral presentation: APL-1702 long-term efficacy and safety for cervical histologic high-grade squamous intraepithelial lesions (HSIL): results from a randomized phase ? global study Scientific Plenary - Scientific Plenary IV: Late Breaking Abstract Session 1, onMarch 17, 2024 )The Society of Gynecologic Oncology (SGO)'s Annual Meeting on Women's Cancer is one of the most prominent global gatherings in the field of gynecologic oncology, bringing together thousands of top experts and scholars from around the world. It showcases the latest research advancements and best clinical practices in the field of gynecologic oncology. Read Asieris' full media release here: https://asieris.com/asieris-to-unveil -results-of-the-international-multicenter-phase-iii-clinical-study-for-1702-a -non-surgical-treatment-for-cervical-hsil-at-the-2024-sgo-annual-meeting/ Cevira is a breakthrough photodynamic drug-device combination product that is being developed for non-surgical treatment of high-grade precancerous lesions of the cervix.Photocure developed Cevira through Phase 1 and Phase 2 trials, and the global rights for development and commercialization were out-licensed toAsieris Meditech Co., Ltd in 2019. Asieris is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases. Note to editors: All trademarks mentioned in this release are protected by law and are registered trademarks ofPhotocure ASA . This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware thatPhotocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. AboutPhotocure ASA Photocure :The Bladder Cancer Company delivers transformative solutions to improve the lives of bladder cancer patients. Our unique technology, making cancer cells glow bright pink, has led to better health outcomes for patients worldwide.Photocure is headquartered inOslo, Norway and listed on theOslo Stock Exchange (OSE: PHO). For more information, please visit us at www.photocure.com, www.hexvix.com, www.cysview.com For further information, please contact:Dan Schneider President and CEOPhotocure ASA Email: ds@photocure.comErik Dahl CFOPhotocure ASA Tel: +4745055000 Email: ed@photocure.comDavid Moskowitz Vice President, Investor RelationsPhotocure ASA Tel: +1 202 280 0888 Email: david.moskowitz@photocure.com Media and IR enquiries: Geir Bjørlo Corporate Communications (Norway ) Tel: +47 91540000 Email: geir.bjorlo@corpcom.no
Click here for more information
© Oslo Bors ASA, source